CEACAM1, a novel serum biomarker for pancreatic cancer
CEACAM1, a novel serum biomarker for pancreatic cancer
复制标题
DOI：
10.1097/mpa.0b013e3180333ae3
复制
发表时间：
2007-05-01
期刊：
影响因子：
2.9
通讯作者：
Logsdon, Craig D.
中科院分区：
文献类型：
--
作者：
Simeone, Diane M.;Ji, Baoan;Logsdon, Craig D.
目的：目前还没有用于胰腺腺癌早期诊断的血清生物标志物。我们最近观察到CEACAM1在胰腺腺癌中的表达升高，并试图确定胰腺癌患者血清CEACAM1水平是否升高。方法：采用定量逆转录-聚合酶链反应法测定胰腺组织样品中CEACAM1信使RNA水平。CEACAM1通过免疫组化定位于腺癌和胰腺导管内瘤变病变。采用双决定因素酶联免疫吸附法评估CEACAM1血清水平，并与血清CA19-9水平进行比较。结果：CEACAM1在胰腺腺癌中的表达水平高于非癌性胰腺（P < 0.0001），且CEACAM1仅局限于肿瘤细胞（95%（45/47）的腺癌和85%（17/20）的胰腺导管内肿瘤3病变）。CEACAM1在91%（74/81）的胰腺癌患者、24%（15/61）的正常患者和66%（35/53）的慢性胰腺炎患者血清中表达，敏感性和特异性均优于CA19-9。CEACAM1联合CA19-9的诊断准确率明显高于CA19-9。结论：CEACAM1在胰腺腺癌中表达，血清CEACAM1水平可作为判断胰腺癌存在的有用指标。血清CEACAM1作为胰腺癌诊断标志物的进一步验证研究是有必要的。
Objectives: Serum biomarkers for early diagnosis of pancreatic adenocarcinoma are not currently available. We recently observed elevated expression of CEACAM1 in pancreatic adenocarcinomas and sought to determine whether serum CEACAM1 levels were elevated in pancreatic cancer patients.Methods: CEACAM1 messenger RNA levels were measured in pancreatic tissue samples using quantitative reverse transcription-polymerase chain reaction. CEACAM1 was localized by immunohistochemistry in adenocarcinomas and in pancreatic intraductal neoplasia lesions. CEACAM1 serum levels were assessed by a double determinant enzyme-linked immunosorbent assay and compared with serum levels of CA19-9.Results: CEACAM1 had higher expression levels in pancreatic adenocarcinomas compared with noncancerous pancreas (P < 0.0001) and was localized to neoplastic cells (95% (45/47) of adenocarcinomas and 85% (17/20) of pancreatic intraductal neoplasia 3 lesions. CEACAM1 was expressed in the sera of 91% (74/81) of pancreatic cancer patients, 24% (15/61) of normal patients, and 66% (35/53) of patients with chronic pancreatitis, with a sensitivity and specificity superior to CA19-9. The combination of CEACAM1 and CA19-9 had significantly higher diagnostic accuracy than CA19-9.Conclusions: CEACAM1 is expressed in pancreatic adenocarcinoma, and serum levels of CEACAM1 serve as a useful indicator for the presence of pancreatic cancer. Additional validation studies on the use of serum CEACAM1 as a diagnostic marker in pancreatic cancer are warranted.